Oliveira, B. d. C. | Search bioRxiv

bioRxiv2026

Single-cell RNA sequencing of CTLA-4 and PD-1 blockade in pulmonary paracoccidioidomycosis highlights a protective transcriptional program mediated by activated Th17 cells, neutrophils and macrophages

Pulmonary paracoccidioidomycosis (PCM) relies on a finely balanced lung-immune network in which Th17, Treg, neutrophils, and macrophages orchestrate fungal control and tissue integrity. Furthermore, within the context of single-cell sequencing, little is known about how immune checkpoint inhibition modulates this balance during systemic mycosis. In a previous study we verified that the blockade of checkpoint molecules (CTLA-4 and PD-1) restores protective immunity that reduces fungal loads, tissue pathology and mortality of infected mice. Here, we have further studied this model by single-cell RNA sequencing on lung leukocytes from mice infected with Paracoccidioides brasiliensis and treated with anti-CTLA-4 or anti-PD-1 antibodies to define the cellular and molecular consequences of checkpoint blockade in vivo. We generated a high-resolution atlas covering T cells, neutrophils, macrophages/monocytes, B cells, NK cells, and epithelial subsets. Checkpoint inhibition consistently remodeled the CD4 T cell compartment toward a Th17-enriched program, with reduced interleukin-10 expressing Treg frequencies and a prominent interleukin-17A (IL-17), C-C chemokine receptor type 2, CXC chemokine (CXC) receptor type 6, CD44 (Il17aCcr2Cxcr6Cd44) signature. This shift was accompanied by the expansion and activation of neutrophils and macrophages expressing tumor necrosis factor and chemokines (including CXC motif chemokine ligand (Cxcl1, Cxcl2 and Ccl4), microbicidal-associated genes (S100 calcium-binding protein A8 and A9), and regulatory mediators such as secretory leukocyte protease inhibitor and interleukin-15. Ligand-receptor and trajectory analyses revealed a reinforced Th17-myeloid communication axis, particularly under CTLA-4 blockade, converging on IL17-centered inflammatory circuits while attenuating canonical Treg checkpoints (cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1, interleukin-10). Together, these data demonstrate that anti-CTLA-4 and anti-PD-1 immunotherapies profoundly rewire the lung-immune microenvironment during PCM, amplifying effector Th17-neutrophil-macrophage networks that benefits protective antifungal activity Our work provides a mechanistic framework for evaluating immune checkpoint inhibitors in chronic fungal infections.

immunology↗

bioRxiv2025

Escherichia coli-induced gut IL-33 release inhibits lung type 2 allergic responses

BackgroundThe incidence of lung allergies is reduced in countries with higher prevalence of infection and environmental exposure to microbes. However, enteric bacterial infections do not always correlate with lower incidence of allergic disorders and how lung immunity to allergens can be regulated by gut exposure to pathogens and their toxins is not fully understood. ObjectiveWe used mouse models of enterotoxigenic Escherichia coli (ETEC) infection and lung allergy to examine how gut exposure to bacteria, or their related toxins, affects allergic lung inflammation. MethodsNaive C57BL/6 mice were infected with enterotoxigenic Escherichia coli (ETEC) or orally treated with the ETEC LT toxin, to mimic enteric bacterial infections. After two weeks, these mice were treated intranasally with Ovalbumin (OVA) and Papain or IL-33, followed by challenge with OVA, to induce allergic lung inflammation that was assessed using multiple readouts. ResultsGut exposure to ETEC significantly inhibited allergic lung inflammation in a LT-dependent manner, as demonstrated by reduced tissue inflammation, less accumulation of type 2 cytokines, and reduced lung numbers of type 2 immune cells such as type 2 innate lymphoid cells (ILC2) and eosinophils. The anti-allergic capacity of LT was associated with reduced ability of lung ILC2s to recognize IL-33. Counterintuitively, deletion of either IL-33 or ILC2s significantly reverted the LT protective effect, suggesting the LT-mediated protection may occur through gut release and local sensing of IL-33. ConclusionsExposure to ETEC protects hosts against allergic lung inflammation through a negative feedback loop regulated by gut IL-33 release and sensing, suggesting a possible new immunological mechanism for reduced lung allergy incidence observed in areas with enteric bacterial infections. Key Messages- Enteric exposure to enterotoxigenic E. coli (ETEC) bacteria or its toxin LT significantly protects hosts against lung type 2 allergic inflammation. - ETEC and LT downregulate the capacity of lung ILC2s to respond to allergen-induced IL-33. - Deletion of IL-33 or ILC2s significantly impairs the protective effect of ETEC and LT, suggesting the presence of a negative feedback loop driven by toxin-induced gut IL-33 release.

immunology↗